Some researchers argue that COVID-19 is a vascular disease as well as a respiratory one and have been testing cardiovascular drugs’ ability to reduce inflammation and fluid in the lungs.
Several trials are testing losartan, a high blood pressure drug that could block the angiotensin receptor that causes inflammation and fluid in the lungs. The Honolulu-based University of Hawaii at Manoa is also set to conduct a trial testing telmisartan, a similar drug. Research is also underway on how statins, drugs that lower cholesterol, treat COVID-19 complications.
Researchers are also conducting trials testing anti-platelet drugs and blood thinners as effective COVID-19 treatments. Blood thinners, which are regularly prescribed to COVID-19 patients to help reduce blood clots, are being studied to discover if they are more effective in high or low doses at New York City-based New York University’s Langone Hospital.
More articles on pharmacy:
5 recent CMS pharmacy policy changes
Eli Lilly testing COVID-19 drug derived from survivor blood
Some pandemic-inspired FDA changes will stick, commissioner says
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
